Olink® Target 48 Immune Surveillance Panel – The Next Frontier in Immune Biomarker Profiling with Absolute Confidence

UPPSALA, Sweden, June 06, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research.

Read more at globenewswire.com